Growth Hormone Deficiency in Prepubertal Children: Predictive Markers of Cardiovascular Disease

Area of Science:

• Pediatric Endocrinology
• Cardiovascular Risk Assessment
• Metabolomics and Epigenetics

Background:

• Cardiovascular (CV) risk factors are present in adults with untreated growth hormone deficiency (GHD).
• Atheromatous plaque development starts in childhood, with GHD children exhibiting impaired cardiac function, dyslipidemia, and body composition abnormalities.
• Emerging epigenetic and metabolomic studies identify specific biomarkers for CV disease risk.

Purpose of the Study:

• To identify key biochemical and clinical markers predicting CV disease in prepubertal children.
• To assess the impact of recombinant human growth hormone therapy on these CV risk markers.
• To review novel epigenetic and metabolomic findings and their clinical applicability.

Main Methods:

• Literature review of existing studies on GHD, CV risk factors, and growth hormone therapy.
• Analysis of biochemical and clinical markers associated with CV disease in prepubertal children.
• Evaluation of recent epigenetic and metabolomic research relevant to GHD and CV risk.

Main Results:

• GHD in children is associated with significant CV risk factors, including dyslipidemia and altered body composition.
• Recombinant human growth hormone therapy shows potential in mitigating some of these CV risk factors.
• Epigenetic and metabolomic profiles offer new avenues for early CV risk detection in GHD children.

Conclusions:

• Prepubertal children with GHD are at elevated risk for cardiovascular disease.
• Recombinant human growth hormone therapy may offer a therapeutic strategy to reduce CV risk.
• Further research into epigenetic and metabolomic markers is crucial for personalized CV risk management in GHD.